アステラス製薬
It transferred 41 of its products in Japan to Alfresa Holdings Corporation for JPY 4.2 billion in 2018 in order to focus on oncology. The company acquired ramosetron, nicardipine and barnidipine from Astellas Pharma in October 2019.